Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Spine Market: Making A Comeback

Executive Summary

In spite of increasing price pressure, the $9 billion global spine market is projected to see low-single-digit growth in the next few years. Driving growth are the pure-play spine companies targeting high-growth segments such as minimally invasive surgery, expandable interbody cases, cervical discs, and deformity.

You may also be interested in...



Spine Market: Pure Plays Continue to Grab Share

Amidst low growth and a potential rebound in the $9 billion global spine market, the pure-play spine companies, including NuVasive, Globus, K2M and LDR, continue to outperform and grab share from the diversified giants. Medtech Insight founder and former CEO Sharon O'Reilly reports on these companies and more from the 2015 North American Spine Society (NASS) conference in Chicago, where the latest news centered around ancillary approaches to fusion, patient-specific tools, robotics, biologics, expandable cages, MIS and cervical discs.

Orthopedics: Bracing For Change

Despite ongoing economic pressures, the worldwide orthopedic market grew 3% in 2014, reaching $34.7 billion. Although consolidation continues to cause uncertainty and disruption in this space, manufacturers at this year’s AAOS meeting were upbeat about the future as they brace for changes in the competitive landscape, health care delivery, and reimbursement.

Stryker Could Bid for Smith & Nephew Soon

Stryker may make bid for Smith and Nephew this week in a deal that would be completed by end of next year, according to analysts. While the deal makes strategic sense, analysts warn it could carry higher regulatory risk.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

OM017181

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel